Sorin Armeanu
Overview
Explore the profile of Sorin Armeanu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tryfonidou M, Schumann S, Armeanu S, Harichandan A, Sivasubramaniyan K, Mollenhauer J, et al.
Cytometry A
. 2014 Mar;
85(5):379-81.
PMID: 24677755
No abstract available.
2.
Warmann S, Furtwangler R, Blumenstock G, Armeanu S, Nourkami N, Leuschner I, et al.
Ann Surg
. 2011 Jun;
254(1):155-62.
PMID: 21670612
Objective: To analyze the outcome of Wilms' tumor patients with primary lung metastases. Summary Background Data: Radiotherapy and/or surgery are used for local control of primary pulmonary Wilms' tumor metastases....
3.
Muhlebach M, Schaser T, Zimmermann M, Armeanu S, Hanschmann K, Cattaneo R, et al.
Cancer Res
. 2010 Sep;
70(19):7620-9.
PMID: 20858718
Primary and secondary cancers of the liver are a significant health problem with limited treatment options. We sought here to develop an oncolytic measles virus (MV) preferentially activated in liver...
4.
Zimmermann M, Armeanu S, Smirnow I, Kupka S, Wagner S, Wehrmann M, et al.
Int J Oncol
. 2009 Apr;
34(5):1247-56.
PMID: 19360338
Availability of an individualized preselection of oncolytic viruses to be used for virotherapy of tumor patients would be of great help. Using primary liver tumor resection specimens we evaluated the...
5.
Warmann S, Armeanu S, Heigoldt H, Ruck P, Vonthein R, Heitmann H, et al.
Pediatr Blood Cancer
. 2009 Feb;
53(2):145-51.
PMID: 19213079
Background: Multidrug resistance is a key factor for the sobering outcome of relapsed and metastatic human hepatoblastoma (HB). Gene directed treatment approaches were recently identified as possible treatment options against...
6.
Beiter T, Zimmermann M, Fragasso A, Armeanu S, Lauer U, Bitzer M, et al.
Exerc Immunol Rev
. 2009 Feb;
14:73-85.
PMID: 19203085
So far, the abuse of gene transfer technology in sport, so-called gene doping, is undetectable. However, recent studies in somatic gene therapy indicate that long-term presence of transgenic DNA (tDNA)...
7.
Seitz G, Krause R, Fuchs J, Heitmann H, Armeanu S, Ruck P, et al.
Oncol Rep
. 2008 Oct;
20(5):1277-82.
PMID: 18949433
Limited treatment results in advanced pediatric liver tumors have emphasised the need for alternative treatment approaches in these malignancies. Photodynamic therapy (PDT) has been proposed as promising treatment approach in...
8.
Armeanu S, Krusch M, Baltz K, Weiss T, Smirnow I, Steinle A, et al.
Clin Cancer Res
. 2008 Jun;
14(11):3520-8.
PMID: 18519785
Purpose: Hepatocellular carcinoma (HCC) displays particular resistance to conventional cytostatic agents. Alternative treatment strategies focus on novel substances exhibiting antineoplastic and/or immunomodulatory activity enhancing for example natural killer (NK) cell...
9.
Venturelli S, Armeanu S, Pathil A, Hsieh C, Weiss T, Vonthein R, et al.
Cancer
. 2007 Apr;
109(10):2132-41.
PMID: 17407132
Background: Innovative epigenetic therapeutics comprise histone deacetylase inhibitors (HDAC-I) and demethylating agents (DA). It was recently found that HDAC-I compounds exhibit profound therapeutic activities against hepatocellular carcinoma (HCC). A comprehensive...
10.
Seitz G, Warmann S, Armeanu S, Heitmann H, Ruck P, Hoffman R, et al.
Int J Oncol
. 2007 Feb;
30(3):615-20.
PMID: 17273762
Treatment of childhood rhabdomyosarcoma is limited by recurrent disease and the development of multidrug resistance. Therefore, novel treatment options are desirable. Photodynamic therapy (PDT) using the photodynamic agent hypericin is...